Ischaemic heart disease and cholesterol. Drug trial deaths cannot be dismissed.
作者信息
Sheldon T A, Song F
出版信息
BMJ. 1994 Apr 16;308(6935):1039, 1041.
Abstract
摘要
相似文献
1
Ischaemic heart disease and cholesterol. Drug trial deaths cannot be dismissed.
BMJ. 1994 Apr 16;308(6935):1039, 1041.
2
Ischaemic heart disease and cholesterol. Optimism about drug treatment is unjustified.
BMJ. 1994 Apr 16;308(6935):1038, 1041.
3
[Coronary mortality lowered by 24%. Convincing results of the LIPID Study on Secondary Prevention].
Z Kardiol. 1998 Apr;87(4 Suppl Uberzeugen):1-3.
4
Prevention of mortality from coronary heart disease with pravastatin.
Biomed Pharmacother. 1999 Oct;53(9):405-8. doi: 10.1016/S0753-3322(99)80119-X.
5
Five-year trial of clofibrate in ischaemic heart disease.
Br Heart J. 1971 Jan;33(1):145.
6
[Heart Protection Study].
Ugeskr Laeger. 2002 Jan 14;164(3):348.
7
[Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].
Lege Artis Med. 2007 Oct;17(10):675-9.
8
Serum cholesterol and ischaemic heart disease.
Atherosclerosis. 1995 Dec;118 Suppl:S1-5.
9
[Early statin treatment in acute coronary syndrome. Is this evidence-based?].
Ugeskr Laeger. 2002 Jul 1;164(27):3519-22.
本文引用的文献
1
Cholesterol lowering and mortality: the importance of considering initial level of risk.
BMJ. 1993 May 22;306(6889):1367-73. doi: 10.1136/bmj.306.6889.1367.
2
Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population.
Ann Med. 1993 Feb;25(1):41-5. doi: 10.3109/07853899309147855.
3
Possibly disappointing results of treatment with gemfibrozil.
N Engl J Med. 1993 Jan 14;328(2):139-40. doi: 10.1056/NEJM199301143280214.
4
Assessing possible hazards of reducing serum cholesterol.
BMJ. 1994 Feb 5;308(6925):373-9. doi: 10.1136/bmj.308.6925.373.
5
[Evaluation of clofibrate therapy in peripheral arteriopathy].
Minerva Med. 1971 Sep 26;62(72):3469-75.
Zotero 插件